JPRN-UMIN000016136
Not Yet Recruiting
N/A
A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-dily fluticasone propionate/salmeterol in elderly patients with asthma - The efficacy of fluticasone furoate/vilanterole in elderly asthmatics
Conditionselderly asthma
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- elderly asthma
- Sponsor
- Toyama City Hospital
- Enrollment
- 20
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Unsle elderly asthma
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
A 24-week study to evaluate the effect of fluticasone furoate/ vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD). - N/AChronic Obstructive Pulmonary Disease (COPD).MedDRA version: 16.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2010-023091-10-DEGlaxoSmithKline Research & Development Ltd408
Active, Not Recruiting
Phase 1
A 24-week study to evaluate the effect of fluticasone furoate/ vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD). - N/AChronic Obstructive Pulmonary Disease (COPD).MedDRA version: 12.1 Level: LLT Classification code 10010952 Term: COPDEUCTR2010-023091-10-NOGlaxoSmithKline Research & Development Ltd3,011
Active, Not Recruiting
N/A
12 week Chronic Obstructive Pulmonary Disease (COPD)studysubjects with Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-024435-16-DEGlaxoSmithKline Research & Development Ltd248
Active, Not Recruiting
N/A
A 12-week study to evaluate the effect of the drug fluticasone furoate/vilanterol at the dose of 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arterial stiffness compared with the drug Tiotropium bromide at the dose of 18 mcg delivered once daily via a HandiHaler in subjects with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2010-024435-16-ITGlaxoSmithKline Research & Development Ltd248
Not Yet Recruiting
Phase 4
Glargine once versus twice dailyCTRI/2023/10/059275surbhi bharti